NCT05091476 is a NA clinical trial of OPTiC System in Age-Related Macular Degeneration, sponsored by OcuDyne, Inc..

Who is sponsoring NCT05091476?

NCT05091476 is sponsored by OcuDyne, Inc..

What drugs are being tested in NCT05091476?

Interventions in NCT05091476: OPTiC System.

What condition does NCT05091476 study?

NCT05091476 studies Age-Related Macular Degeneration.

Is NCT05091476 still recruiting?

NCT05091476 is currently completed. Last updated 13 February 2025.

Last reviewed 2025-02-13 · How we verify

NCT05091476

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

OcuDyne System in the Treatment of AMD

Completed NA Last updated 13 February 2025

What this trial tests

NA trial testing OPTiC System in Age-Related Macular Degeneration in 17 participants. Completed in 1 October 2024.

Timeline

27 February 2023

Primary endpoint
31 July 2024

1 October 2024

Quick facts

Lead sponsor	OcuDyne, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	17
Start date	27 February 2023
Primary completion	31 July 2024
Estimated completion	1 October 2024
Sites	2 locations across Argentina

Drugs / interventions tested

OPTiC System

Conditions studied

Age-Related Macular Degeneration — all drugs for Age-Related Macular Degeneration →

Sponsor

OcuDyne, Inc.

Who can join

60 and older, any sex, with Age-Related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Feasibility of the OcuDyne OPTiC System in patients with late-stage non-exudative age-related macular degeneration.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Age-Related Macular Degeneration

Currently open trials in the same condition.

NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) · Phase 2, PHASE3 · recruiting
NCT06619405 — AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance · NA · recruiting
NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
NCT06662162 — Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration · NA · recruiting

Other OcuDyne, Inc. trials

Trials by the same sponsor.

NCT06015633 — Ocular, Vascular, and Genetic Findings in AMD Patients · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05091476 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by OcuDyne, Inc.
Last refreshed: 13 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05091476.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing